Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24?Weeks of Treatment

摘要

Introduction Exenatide is gradually released from exenatide once weekly (QW) microspheres, and at steady state, consistently controls glycated hemoglobin (HbA1c) in patients with type 2 diabetes (T2D). This post hoc analysis examined the timing to onset of clinical responses and their correlations with exenatide concentrations after initiation of exenatide QW in patients with T2D. Methods Trial data were retrospectively analyzed to explore the early clinical responses to exenatide QW, including the relationship of exenatide concentration with its effects on efficacy [fasting plasma glucose (FPG), HbA1c, and body weight] and tolerability (nausea and vomiting). Exenatide QW efficacy and tolerability data were from DURATION-5, a 24-week, randomized, comparator-controlled trial [intent-to-treat (ITT) population]. Exenatide concentrations were measured in a patient subset (pharmacokinetic population). Results In the ITT ( n =?129)/pharmacokinetic ( n =?72) populations, baseline FPG, HbA1c, and body weight were 173/173?mg/dL, 8.5%/8.4%, and 97/98?kg, respectively. Exenatide concentrations gradually increased until reaching steady state at week?8. By week?4, the FPG reduction (?32.4?mg/dL) was 94% of the week?24 reduction (?34.6?mg/dL). Reductions in HbA1c began by week 4 (?0.6%) and stabilized by week?14 (week?24: ?1.6%). Weight reduction at week?4 was ?0.7?kg and decreased further (week?24: ?2.3?kg). Peak nausea (7.2%) and vomiting (2.4%) occurred at weeks?6–8, declining thereafter. Conclusion Clinically relevant responses to exenatide QW were evident by week?4, after exenatide concentration passed the therapeutic threshold but before steady state was achieved. Trial Registration ClinicalTrials.gov identifier: NCT00877890. Funding AstraZeneca.